|Bid||0.0500 x 0|
|Ask||0.0510 x 0|
|Day's range||0.0480 - 0.0510|
|52-week range||0.0220 - 0.1500|
|Beta (5Y monthly)||0.63|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Generally speaking long term investing is the way to go. But that doesn't mean long term investors can avoid big...
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
Every investor in Prescient Therapeutics Limited (ASX:PTX) should be aware of the most powerful shareholder groups...
In 2016 Yatomi-Clarke Lee was appointed CEO of Prescient Therapeutics Limited (ASX:PTX). This analysis aims first to...
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...